Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC).

Gómez, Pedro López; Roché, Henri; Costa, F.; Segalla, J. G. M.; Pinczowski, Hélio; Filho, Sebastião Cabral; Ciruelos, Eva; Eyll, Brigitte M. Van; Baselga, J.

doi:10.1200/jco.2010.28.15_suppl.1083

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,3,6 This adverse event is also being seen with the targeted agents such as pazopanib and sorafenib. 7,8…”

Section: Introductionmentioning

confidence: 99%

“…1,3,6 This adverse event is also being seen with the targeted agents such as pazopanib and sorafenib. 7,8 PPE is considered to be widely underreported with varying descriptions of presentation and grading. 3 A literature search of OVID, PubMed and IPA revealed that the majority of case reports describe instances of PPE associated with malignancies such as breast or ovarian cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature

Harris

Wang

Carulli

2013

J Oncol Pharm Pract

View full text Add to dashboard Cite

Docetaxel-associated palmar-plantar erythrodysesthesia is rarely reported in literature, particularly when used in the treatment of sarcomas. Here, we report a case of docetaxel-related palmar-plantar erythrodysesthesia in a 28-year-old male with recurrent Ewing sarcoma. Although palmar-plantar erythrodysesthesia has been seen in the literature for 30 years, there has still been little progress in understanding and appropriately addressing this adverse effect. This case report and literature review illustrates an infrequently documented adverse skin reaction and discusses the etiology, presentation, and available treatment options for palmar-plantar erythrodysesthesia.

show abstract

“…1,3,6 This adverse event is also being seen with the targeted agents such as pazopanib and sorafenib. 7,8…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature

Harris

Wang

Carulli

2013

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

Management of hand-foot skin reaction (HFSR)/hand-foot syndrome (HFS) in SOLTI-0701: A double-blind, randomized phase IIb study comparing sorafenib (SOR) versus placebo (PL) in combination with capecitabine (CAP) in patients (pts) with advanced breast cancer (BC).

Cited by 1 publication

References 0 publications

Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature

Docetaxel-associated palmar-plantar erythrodysesthesia: A case report and review of the literature

Contact Info

Product

Resources

About